| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalent | 1,626,610 | 1,316,594 | ||
| Prepaid expenses and other receivable | 396,901 | 163,933 | ||
| Total current assets | 2,023,511 | 1,480,527 | ||
| Prepaid expenses, related party , non-current-Related Party | 1,500,000 | 1,500,000 | ||
| Total assets | 3,523,511 | 2,980,527 | ||
| Accounts payable - related party-Related Party | 5,631 | 8,154 | ||
| Other payables and accrued liabilities | 75,615 | 110,767 | ||
| Income tax payables | - | 0 | ||
| Accrued liability - related party-Related Party | 12,893,333 | 8,768,333 | ||
| Franchise tax payable | - | 0 | ||
| Derivative liabilities | 385,355 | 187,941 | ||
| Preferred stock, value-Series APreferred Stock | - | 0 | ||
| Total current liabilities | 13,359,934 | 9,075,195 | ||
| Preferred stock, value-Series AAPreferred Stock | - | 0 | ||
| Total liabilities | 13,359,934 | 9,075,195 | ||
| Common stock, 0.0001 par value 250,000,000 shares authorized 38,280,870 and 36,680,870 shares issued as of september 30, 2025 and december 31, 2024, respectively | 3,828 | 3,758 | ||
| Additional paid-in capital | 27,135,769 | 26,076,445 | ||
| Accumulated deficit | -36,377,641 | -31,576,492 | ||
| Treasury stock, at cost 515,281 and 486,979 shares as of september 30, 2025 and december 31, 2024, respectively | 598,379 | 598,379 | ||
| Total stockholders (deficit) equity | -9,836,423 | -6,094,668 | ||
| Total liabilities and stockholders (deficit) equity | 3,523,511 | 2,980,527 | ||
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)